April 12, 2021Vascular Medicine

Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature

View Full Paper

Ask AI

Bookmark

Why the study?

Inhibition of the VEGF pathway impairs vascular wall integrity, potentially resulting in arterial aneurysm or dissection, prompting evaluation of this potential safety risk in cancer patients.

Are systemic VEGF inhibitors associated with arterial aneurysm and dissection in patients with cancer?

Population

240 cases of arterial aneurysm/dissection associated with VEGF inhibitors

Design

Postmarketing review of the FAERS database and literature

Authors

CCConnie ChengNorthwell Health MNMichelle Nadeau NguyenUnited States Food and Drug Administration ANAfrouz NayernamaUnited States Food and Drug Administration

Discussion

Member takes

Implication

VEGF inhibitors may be linked to aneurysm/dissection; leaves open need for prospective studies to confirm causality and guide monitoring.

Structured PICO

Are systemic VEGF inhibitors associated with arterial aneurysm and dissection in patients with cancer?

Population

240 cases of patients with cancer treated with FDA-approved systemic vascular endothelial growth factor (VEGF) inhibitors who developed arterial (including aortic) aneurysm/dissection.

Intervention

Systemic vascular endothelial growth factor (VEGF) inhibitors

Outcome

Arterial (including aortic) aneurysm/dissectionsafety

Systemic VEGF inhibitors may carry a rare but life-threatening class-effect risk of arterial aneurysm and dissection, warranting awareness among cardiovascular and oncology professionals.

Cite This Study

Cheng et al. (2021) studied this question.

synapsesocial.com/papers/6a87d653350e059174ad3983 https://doi.org/10.1177/1358863x211006470

View Full Paper

Ask AI

Bookmark